• Himanshu Garg Department of Respiratory, Artemis Hospital, Noida, Uttar Pradesh, India.
  • Pratibha Dogra Department of Respiratory, Artemis Hospital, Noida, Uttar Pradesh, India
  • Mayank Saxena Department of Respiratory, Artemis Hospital, Noida, Uttar Pradesh, India.


 Objective: One of the major causes of ventilator-associated pneumonia (VAP) in hospital settings is Acinetobacter baumannii. The propensity of acquiring antimicrobial resistance rapidly through a multiple number of mechanisms makes the selection of an appropriate empirical antimicrobial agent exceedingly challenging for this pathogen.

Methods: The present case report explores the option of treating VAP infection due to carbapenem-resistant pathogens with antibiotic adjuvant entities.

Results: We present a case of VAP due to carbapenem-resistant A. baumannii that was successfully treated with CSE-1034 and colistin combination therapy.

Conclusion: Early recognition and appropriate antibiotic therapy are essential to eliminate poor outcomes in multidrug-resistant (MDR) bacterial infections. The present case highlights the antibiotic adjuvant entity “CSE-1034†as an empiric option for the treatment of VAP due to MDR A. baumannii in intensive care unit.

Keywords: CSE1034, Colistin, Pneumonia, Acinetobacter baumannii, Carbapenamases.


1. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007;51:3471-84.
2. Arjuna A, Nandi D. Acinetobacter main cause of hospital acquired infections: A review. Asian J Pharm Clin Res 2017;10:53-6.
3. Doi Y, Murray GL, Peleg AY. Acinetobacter baumannii: Evolution of antimicrobial resistance-treatment options. Semin Respir Crit Care Med 2015;36:85-98.
4. Almomani B, Al-Gharaibeh R, Al-Mahasneh F, Samrah S. Multidrug resistant Acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality. Eur Respir J 2014;44:2071.
5. Siegel RE. Emerging gram-negative antibiotic resistance: Daunting challenges, declining sensitivities, and dire consequences. Respir Care 2008;53:471-9.
6. Ganguly NK, Arora NK, Chandy SJ, Fairoze MN, Gill JP, Gupta U, et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J Med Res 2011;134:281-94.
7. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Acinetobacter baumannii 2002-2008: Increase of carbapenem-associated multiclass resistance in the United States. Microb Drug Resist 2010;16:209-15.
8. Hu FP, Guo Y, Zhu DM, Wang F, Jiang XF, Xu YC, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin Microbiol Infect 2016;22 Suppl 1:S9-14.
9. Lin MF, Lan CY. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases 2014;2:787-814.
10. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT. Type 2 diabetes and pneumonia outcomes: A population-based cohort study. Diabetes Care 2007;30:2251-7.
11. Song SW, Kim KT, Ku YM, Park SH, Kim YS, Lee DG, et al. Clinical role of interstitial pneumonia in patients with scrub typhus: A possible marker of disease severity. J Korean Med Sci 2004;19:668-73.
12. Chaudhary M, Mir MA, Ayub SG; Protocol Group. Safety and efficacy of a novel drug elores (ceftriaxone sulbactam disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: A post-marketing surveillance study. Braz J Infect Dis 2017;21:408-17
13. Chaudhary M, Payasi A. Incidence, prevalence and control of multidrug resistant (MDR) carbapenemase producing Acinetobacter baumanii in Indian intensive care units. J Pharm Res 2013;7:175-80.
14. Sathe P, Maddani S, Kulkarni S, Munshi N. Management of ventilator associated pneumonia with a new antibiotic adjuvant entity (ceftriaxone sulbactam disodium edetate)-a novel approach to spare carbapenems. J Crit Care 2017;41:145-9.
15. Chaudhary M, Payasi A. Synergy of a novel antibiotic adjuvant entity against multi drug resistant Enterobacteriaceae. Am J Infect Dis 2013;9:94-103.
16. Chaudhary M, Payasi A. A randomized, open-label, prospective, multicenter Phase-III clinical trial of Elores in lower respiratory tract and urinary tract infections. J Pharm Res 2013;6:409-14.
17. Lee CS, Doi Y. Therapy of infections due to carbapenem-resistant gram-negative pathogens. Infect Chemother 2014;46:149-64.
18. Lambert RJ, Hanlon GW, Denyer SP. The synergistic effect of EDTA/antimicrobial combinations on Pseudomonas aeruginosa. J Appl Microbiol 2004;96:244-53.
19. Singh AP, Gupta DU, Das S. Monitor the use of antibiotics in intensive care units with special focus on restricted antibiotics in tertiary care hospital of India. Asian J Pharm Clin Res 2016;9:256-9.
602 Views | 581 Downloads
How to Cite
Garg, H., P. Dogra, and M. Saxena. “SUCCESSFUL TREATMENT OF VENTILATOR ASSOCIATED PNEUMONIA CAUSED BY MULTIDRUG RESISTANT ACINETOBACTER BAUMANNII WITH A COMBINATION THERAPY OF CSE1034 AND COLISTIN: A CASE REPORT.”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 11, no. 2, Feb. 2018, pp. 1-3, doi:10.22159/ajpcr.2018.v11i2.21619.
Case Study(s)